Clinical trials: Continuous Insulin Infusion System
Diabetes Mellitus, Type 2
A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump
This study looks at the effect and safety of a new fast-acting insulin (NNC0471-0119) in people with type 2 diabetes when given by an insulin pump.
- Trial name
- NCT07068295
- Testing
- NNC0471-0119 H, Insulin Aspart
- Where
- Germany
- Volunteers
- 65 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy
Achieving near-normoglycemia has been established as the main objective for most patients with type 1 diabetes (T1DM). However, insulin dosing is an empirical process and its success is highly dependent on the patients' and…
- Trial name
- NCT01550809
- Testing
- iBolus, tBolus (traditional bolus)
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Type 1 Diabetes
Psychological Aspects and Insulin Pump Therapy
The Continuous Subcutaneous Insulin Infusion (CSII) might have an impact on psychological distress and some psychological factors might be predictors of metabolic control; however, very few studies conducted so far were…
- Trial name
- NCT02138188
- Where
- Italy
- Volunteers
- 36 people
- Sponsor
- Universita di Verona
Type 1 Diabetes
Carbohydrate and Insulin Requirements During Prolonged Fasted Exercise
The purpose of this study is to compare the time spent in glucose target range (4.0-10.0 mmol/L) during exercise and in recovery using three different management strategies for prolonged aerobic exercise: A) carbohydrate dose of…
- Trial name
- NCT04383015
- Testing
- Exercise strategies
- Where
- Canada
- Volunteers
- 15 people
- Sponsor
- York University
Diabetes Mellitus, Type 1
A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps
The main purpose of this study is to compare LY900014 to insulin lispro (Humalog) in participants with type 1 diabetes who are using an insulin pump and have high blood sugar after eating.
- Trial name
- NCT04276207
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes, Type 2 Diabetes
Evaluation of the Accuracy of the Abbott Sensor Based Interstitial Glucose Monitoring System
The purpose of this study is to demonstrate point accuracy of the Abbott Sensor Based Glucose Monitoring (GM) System interstitial glucose results against Reader capillary Blood Glucose (BG) reference using the Consensus Error…
- Trial name
- NCT02073058
- Testing
- No treatment
- Where
- 4 sites in United States
- Volunteers
- 75 people
- Sponsor
- Abbott Diabetes Care
Type 1 Diabetes
Evaluation of The Postprandial Impact of Automated Priming Bolus for Full Closed Loop Insulin Delivery
The purpose of this study is to understand the impact of the automated priming boluses on the safety and feasibility of a new fully automated AP controller.
- Trial name
- Rocket-BPS (NCT05528770)
- Testing
- FCL+BPS, FCL
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Marc Breton
Insulin Resistance, Endothelial Dysfunction
Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance
The hypothesis is that GHRP-3 will exert beneficial effects on endothelial function and insulin resistance in older men and women via hormonal (GH, IGF-I, IGFBP-3,-1, insulin) and non-hormonal actions (anti-inflammatory).
- Trial name
- NCT00846872
- Testing
- GHRP-3 low dose, GHRP-3 high dose, Saline
- Volunteers
- healthy volunteers welcome
- Sponsor
- Tulane University Health Sciences Center
Type 1 Diabetes, Dermatologic Complication
Prevention of Skin Problems With Diabetes Devices in Pediatric Patients
A Cluster-controlled Intervention Trial regarding Prevention of Dermatological Complications towards use of Continuous glucose monitoring and insulin pumps in pediatric patients with Type 1 Diabetes.
- Trial name
- NCT04258904
- Testing
- Skin Care Program
- Where
- Denmark
- Volunteers
- 236 people
- Sponsor
- Copenhagen University Hospital at Herlev
Type 1 Diabetes Mellitus
FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump
This is an exploratory, single-center, randomized, open label, active-controlled, complete cross-over trial comparing safety and efficacy of Fiasp® versus NovoLog® when used in the Medtronic MiniMed 670G system in subjects with…
- Trial name
- NCT03977727
- Testing
- Fiasp®, Novolog®, 670G hybrid closed loop continuous subcutaneous insulin infusion system
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Texas Diabetes & Endocrinology, P.A.
Diabetes Mellitus, Type 1
Evaluation of Novel Trend Arrow Adjustment Tool for Diabetes Patients Using Continuous Glucose Monitoring to Guide Insulin Bolus Adjustment (TAAT Study)
Continuous glucose monitoring (CGM) provides up to 288 blood glucose levels per day, updated every 5 minutes and displayed in real-time on the insulin pump, which can be used to enhance delivery of insulin through pump therapy.
- Trial name
- TAAT (NCT02064647)
- Testing
- Trend Arrow Adjustment Tool, 10/20% bolus adjustment
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Children's Hospital of Eastern Ontario
Diabetes Mellitus, Type 2
Comparison of Glycaemic Fluctuation and Oxidative Stress Between Two Short-term Therapies for Type 2 Diabetes
The purpose of this study is to compare the blood glucose control, glycaemic fluctuation and oxidative stress for Type 2 Diabetes between two therapies, one is glargine combined with oral drugs and the other is continuous…
- Trial name
- COGFOST (NCT02526810)
- Testing
- insulin lispro, Insulin Glargine
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Type 2 Diabetes Mellitus
Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients
The purpose of this study is to investigate and evaluate the effects of different interventions (1.continuous subcutaneous insulin infusion,2.multiple daily injections, 3.anti-hyperglycemic agents) on glycemic control, B-cell…
- Trial name
- NCT00147836
- Testing
- Human Insulin (Novolin-R, Novo Nordisk), H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland, Pre-meal
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Sun Yat-sen University
Diabetes Mellitus, Type 1
YpsoPump Occlusion Detection Algorithm: Collection of Real-world Data for In-silico Evaluation of a New Software Algorithm to Refine Occlusion Detection in Subjects With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A common difficulty related to the insulin pumps are occlusions of the insulin infusion set (IIS). This study aims to evaluate the performance of a new software algorithm to detect catheter-occlusion in silico in order to refine…
- Trial name
- NCT05096325
- Testing
- YpsoPump® insulin pump system
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 40 people
- Sponsor
- mylife Diabetes Care AG
Diabetes Mellitus, Type I
The Effectiveness of Continuous Glucose Monitoring in Diabetes Treatment for Infants and Young Children
The purpose of this study is to see if the use of a real-time glucose sensor improves diabetes control in young children (less than 4 years old) with Type I diabetes when they are initiated on insulin pump therapy.
- Trial name
- Gerber RTSA (NCT00875290)
- Testing
- Real-time glucose sensor
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Seattle Children's Hospital
Diabetes, Diabetes Mellitus, Type 1
A Research Study of How Faster-acting Insulin Aspart Moves Into, Through, and Out of the Body and How it Works in the Body When Given Through an Insulin Pump to People With Type 1 Diabetes
The aim of the study is to compare the pharmacokinetics (i.e. the course of the blood concentrations of the administered trial drug) of faster-acting insulin aspart (faster aspart), and the currently marketed formulation of…
- Trial name
- NCT03215498
- Testing
- Faster-acting insulin aspart, Insulin aspart
- Where
- Germany
- Volunteers
- 58 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus
Primary objective: To demonstrate the superiority of insulin glulisine over insulin aspart and insulin lispro administered by external pump in term of unexplained hyperglycemia and/or infusion set occlusion.
- Trial name
- PUMP (NCT00607087)
- Testing
- Insulin glulisine, Insulin lispro, Insulin aspart
- Where
- 12 sites in United States, Australia and 10 more
- Volunteers
- 289 people
- Sponsor
- Sanofi
Type 1 Diabetes, Type 2 Diabetes
Comparison of Insulin Pump and MDI for Pregestational Diabetes During Pregnancy
This study is investigating whether insulin treatment with the insulin pump or with multiple daily injections (MDI) gives better outcomes for mother and baby in pregnant women with pregestational diabetes.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Pregnancy
- Trial name
- NCT02064023
- Testing
- insulin pump, multiple daily insulin injection
- Where
- 2 sites in Canada
- Volunteers
- 2 people
- Sponsor
- University of British Columbia
Type 1 Diabetes
Closing the Loop in Youth With Type 1 Diabetes in the Home Setting
Type 1 diabetes (T1D) is one of the most common chronic childhood diseases requiring life-long insulin therapy. Children and adolescents with T1D need regular insulin injections or the continuous insulin delivery using an insulin…
- Trial name
- NCT01221467
- Testing
- Overnight closed-loop
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- University of Cambridge
Diabetes Mellitus, Type 1
Study to Compare Intraperitoneal Insulin to Subcutaneous Insulin Administration in Type 1 Diabetes Mellitus
The purpose of this study is to compare intraperitoneal (IP) therapy to subcutaneous administration of insulin regarding safety, glycemic control and number of episodes of hypoglycemia in patients with type 1 diabetes mellitus.
- Trial name
- NCT00286962
- Testing
- MIP 2007C implantable insulin pump, continuous subcutaneous insulin infusion (CSII) or MDI
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Medical Research Foundation, The Netherlands